Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Martin E. Cearnal net worth and biography

Martin Cearnal Biography and Net Worth

SVP of Cumberland Pharmaceuticals

Prior to joining Cumberland as Senior Vice President of Commercial Development in 2008, Mr. Cearnal served as President and Chief Executive Officer of Physicians World. During his 15-year tenure, the company became the largest provider of continuing medical education before its acquisition by Thomson Healthcare in 2000. He served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. During his more than 49 years in the healthcare industry, Mr. Cearnal has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox®, and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles, culminating in his position as Vice President, Marketing for International Operations. Mr. Cearnal has also served on Cumberland’s Board of Directors since 2004. He is a graduate of Southeast Missouri State University.

What is Martin E. Cearnal's net worth?: The estimated net worth of Martin E. Cearnal is at least $178,258.32 as of July 6th, 2021. Mr. Cearnal owns 165,054 shares of Cumberland Pharmaceuticals stock worth more than $178,258 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Cearnal may own. Learn More about Martin E. Cearnal's net worth.
How do I contact Martin E. Cearnal?: The corporate mailing address for Mr. Cearnal and other Cumberland Pharmaceuticals executives is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. Cumberland Pharmaceuticals can also be reached via phone at (615) 255-0068 and via email at [email protected]. Learn More on Martin E. Cearnal's contact information.
Has Martin E. Cearnal been buying or selling shares of Cumberland Pharmaceuticals?: Martin E. Cearnal has not been actively trading shares of Cumberland Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, July 30th, Martin E. Cearnal bought 105 shares of Cumberland Pharmaceuticals stock. The stock was acquired at an average cost of $3.31 per share, with a total value of $347.55. Following the completion of the transaction, the senior vice president now directly owns 165,054 shares of the company's stock, valued at $546,328.74. Learn More on Martin E. Cearnal's trading history.
Who are Cumberland Pharmaceuticals' active insiders?: Cumberland Pharmaceuticals' insider roster includes Martin Cearnal (SVP), Joseph Galante (Director), A. J. Kazimi (CEO), A.J. Kazimi (CEO), Kenneth Krogulski (Director), and William Sumas (EVP). Learn More on Cumberland Pharmaceuticals' active insiders.

Martin E. Cearnal Insider Trading History at Cumberland Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/30/2021	Buy	105	$3.31	$347.55	165,054
7/28/2021	Buy	105	$3.42	$359.10
7/26/2021	Buy	105	$3.39	$355.95
7/23/2021	Buy	105	$3.35	$351.75
7/21/2021	Buy	105	$3.26	$342.30	165,054
7/19/2021	Buy	105	$3.23	$339.15
7/16/2021	Buy	105	$3.28	$344.40
7/14/2021	Buy	105	$3.33	$349.65	165,054
7/12/2021	Buy	105	$3.33	$349.65	165,054
7/8/2021	Buy	105	$3.18	$333.90	165,054
7/6/2021	Buy	105	$3.14	$329.70	165,054
7/2/2021	Buy	105	$2.94	$308.70
6/30/2021	Buy	105	$2.93	$307.65
6/28/2021	Buy	105	$3.16	$331.80	161,904
6/25/2021	Buy	105	$3.09	$324.45	161,904
6/23/2021	Buy	105	$3.07	$322.35	161,904
6/21/2021	Buy	105	$3.14	$329.70
6/18/2021	Buy	105	$2.99	$313.95
6/16/2021	Buy	105	$3.09	$324.45	161,904
6/14/2021	Buy	105	$3.11	$326.55	161,904
6/11/2021	Buy	105	$3.18	$333.90	161,904
6/9/2021	Buy	105	$3.14	$329.70	161,904
6/7/2021	Buy	105	$2.94	$308.70	161,904
6/3/2021	Buy	105	$2.81	$295.05	161,904
6/1/2021	Buy	105	$2.94	$308.70	161,904
5/28/2021	Buy	105	$2.93	$307.65
5/26/2021	Buy	105	$2.85	$299.25	161,904
5/24/2021	Buy	105	$3.02	$317.10	161,904
5/21/2021	Buy	105	$3.06	$321.30
5/19/2021	Buy	105	$2.83	$297.15
5/17/2021	Buy	5,805	$2.83	$16,428.15	148,814
5/14/2021	Buy	5,105	$2.77	$14,140.85	148,814
5/12/2021	Buy	105	$2.86	$300.30	148,814
5/10/2021	Buy	105	$2.71	$284.55	148,814
5/7/2021	Buy	105	$2.73	$286.65	148,814
5/5/2021	Buy	105	$2.73	$286.65	148,814
5/3/2021	Buy	105	$2.66	$279.30	148,814
4/30/2021	Buy	105	$2.78	$291.90	148,814
4/28/2021	Buy	80	$2.94	$235.20	148,814
4/26/2021	Buy	105	$2.97	$311.85	148,814
4/23/2021	Buy	105	$2.99	$313.95	148,814
4/21/2021	Buy	105	$2.97	$311.85	148,814
4/19/2021	Buy	105	$3.04	$319.20	148,814
4/16/2021	Buy	105	$3.03	$318.15	148,814

Martin E. Cearnal Buying and Selling Activity at Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $1.08

$1.05

$1.13

50 Day Range

MA: $1.23

$1.11

$1.31

2 Week Range

Now: $1.08

$1.05

$2.36

Volume

27,790 shs

Average Volume

17,359 shs

Market Capitalization

$15.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22